Vol. 23 No. 2 (2025): Blood Transfusion 2-2025 (March-April)
Full Issue
Requires Subscription
pdf
Review
-
Noninvasive fetal blood group antigen genotyping: Noninvasive fetal blood group antigen genotyping
-
Comprehensive analysis of parvovirus B19 infection in blood donors: epidemiological trend and implications for transfusion safety and management strategies in Italy: Epidemiology and transfusion safety of B19V in donors
Original article
-
Rh disease in Mexico: evaluating regional and institutional differences in treatment availability and disease management: Rh disease awareness in Mexico
-
How do we transfuse children in Italy? Results of a national survey: National survey on pediatric transfusions in Italy
-
Red blood cell transfusion in patients undergoing elective primary glioblastoma resection: RBC transfusion in glioblastoma patients
-
Quality and stability studies of red blood cell concentrates from umbilical cord blood compared to their adult counterparts: CB-RBC quality and stability studies compared to adult RBC
-
Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT: Anti-HLA and DSA management in Italian Transplant Programs
Brief report
-
The -72G>A nucleotide substitution impairs transcription of the ABO gene via reduction of promoter activity: Substitution mutation leads to the “3” subgroup phenotype
-
CD36 antibodies in isoimmunised African-origin pregnant women: three years experience in Spain: CD36 antibodies in isoimmunised African-origin pregnant women
Letter to the Editor
-
Cryoprecipitate should not be the essential medicine recommended by the WHO to treat haemophilia: Factor VIII concentrate rather than cryoprecipitate for Haemophilia
-
Recommending defunct therapies is a safety risk for hemophilia: Therapies and safety risks in haemophilia
-
Response to comments on inclusion of cryoprecipitate, pathogen-reduced on the WHO model lists of essential medicines for adults and children: a call for action: Responses to comments on Cryo-PR listing on the WHO EML